Research programme: small molecule immunomodulators - Aptorum Group/Yale University
Latest Information Update: 28 May 2025
At a glance
- Originator Yale University
- Developer Aptorum Group; Yale University
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in Hong Kong
- 28 May 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 May 2025 No recent reports of development identified for preclinical development in Cancer in Hong Kong